All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-04-23.
From the record
VolitionRx Limited's filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-04-23) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
10 filed years; profitable in 0 of 10.
From the record
VolitionRx Limited's 10 filed years say what it did: it rose in 6 of 8 years; the deepest fall was 76% from fiscal 2012 to fiscal 2020; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: VolitionRx Limited's shareholder treatment is put at 4.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 47% of 18 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 596%: owes 596¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, VolitionRx Limited's shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 596 cents per dollar of assets, and net share issuance: its share count grew 23.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 46% of 17 in its family; net margin -1352.2%.
From the record
VolitionRx Limited's standing among 17 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 26% by size; a net margin of -1352.2% ranks in the bottom 21%; revenue growth of 78% a year over the last 3 filed years ranks in the top 9% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 18% of 15 in its family for leadership; chief executive since 2013.
From the record
VolitionRx Limited's leadership, from its insiders' filings and its current reports: the chief executive on the record is Reynolds, Cameron John (President and CEO, as filed), filing under that title since 2013-08-27, 13.2 years (top 12% of its family); the 18 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 25%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 18 people in charge now (top 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 34% of 16 in its family for room to expand.
From the record
VolitionRx Limited's room to grow, from the newest filed statements (fiscal 2025): cash of $1 million against debt of $7 million leaves -81% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is -1144.7% of revenue (bottom 22%); research spending of 583.6% of revenue (top 22%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 43% of 17 in its family for growth drivers.
From the record
VolitionRx Limited's growth drivers, from the filed years to fiscal 2025: the newest year grew 40.1% (top 9%); research spending grew -13% a year (bottom 26%); capital spending grew -61.5% a year (bottom 10%) (its annual reports). VolitionRx Limited tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 44% of 16 in its family for expectations against reality.
From the record
VolitionRx Limited's newest year against its own record: revenue of $2 million in fiscal 2025 came in 30.2% below the $2 million its prior three years' pace pointed to (bottom 17% of its family); net income of $23 million against a prior three-year average of $31 million (top 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 9%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made